Loading color scheme

ONC-392

Novel antibodies selectively abrogate immune evasion in tumor microenvironment but preserve immune checkpoint against adverse events.

ONC-781, 782, 783, and 784

Targeting cancer cells through chimeric antigen receptors T cells (ONC-782), bi-specific antibodies (ONC-783) and antibody-drug conjugates (ONC-784).

OncoC4 has a pipeline of best-in-class and first-in-class immunotherapy products that are moving through preclinical testing.

Developing unique drugs that uncouple therapeutic effects and immunotherapy-related adverse effects.

   Scientific discoveries drive explosive immunotherapy.   

YANG LIU, PHD

CHIEF EXECUTIVE OFFICER & CHIEF SCIENTIFIC OFFICER

WuXi Biologics and OncoC4 Establish Exclusive CDMO Partnership

SHANGHAI and ROCKVILLE, Md., May 26, 2021 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, and OncoC4, Inc., a privately-held, clinical-stage biopharmaceutical company, today announced that the companies have entered into an exclusive contract development and manufacturing partnership for OncoC4's full pipeline…

Read more

Merck to Acquire OncoImmune

KENILWORTH, N.J., & ROCKVILLE, Md.--Merck (NYSE: MRK), known as MSD outside the United States and Canada, and OncoImmune, a privately-held, clinical-stage biopharmaceutical company, today announced that the companies have entered into a definitive agreement pursuant to which Merck, through a subsidiary, will acquire all outstanding shares of OncoImmune for an…

Read more

OncoImmune Launches First-in-human Clinical Trial for ONC-392

OncoImmune, Inc. announced today that it has dosed the first patient in the first-in-human clinical trial of ONC-392, its novel, next generation anti-CTLA-4 antibody, at the University of California (UC) Davis Comprehensive Cancer Center on September 16, 2020.

Read more